Patents Assigned to THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SER.
-
Publication number: 20230287055Abstract: Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.Type: ApplicationFiled: January 31, 2023Publication date: September 14, 2023Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Ser.Inventors: Peter Collins, Bo Liang, Shirin Munir, Anne Schaap Nutt, Ursula Buchholz, Natalie Mackow, Peter Kwong, Barney Graham, Jason McLellan
-
Publication number: 20210079112Abstract: Provided herein are methods of treating a subject with cancer with a combination of antibody-IR700 molecules and immunomodulators. In particular examples, the methods include administering to a subject with cancer a therapeutically effective amount of one or more antibody-IR700 molecules, where the antibody specifically binds to a cancer cell surface protein, such as a tumor-specific antigen. The methods also include administering to the subject a therapeutically effective amount of one or more immunomodulators (such as an immune system activator or an inhibitor of immuno-suppressor cells), either simultaneously or substantially simultaneously with the antibody-IR700 molecules, or sequentially (for example, within about 0 to 24 hours). The subject or cancer cells in the subject (for example, a tumor or cancer cells in the blood) are then irradiated at a wavelength of 660 to 740 nm at a dose of at least 1 J/cm2.Type: ApplicationFiled: April 9, 2019Publication date: March 18, 2021Applicant: The United States of America, as represented by the Secretary, Department of Health and Human SerInventors: Hisataka Kobayashi, Peter Choyke
-
Publication number: 20200049782Abstract: Kinetic monitoring of in vivo metabolism of labelled tracers is based on singular value decomposition or Tucker Decomposition of magnetic resonance spectral image data. Data decomposition is used in conjunction with rank reduction to improve signal-to-noise ratio. Rank reduction can be applied in one or more of a spectral, spatial, or temporal dimension. Rank is generally reduced based on a number of expected analytes/metabolites or fit of measured data to a model.Type: ApplicationFiled: February 14, 2018Publication date: February 13, 2020Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Ser..Inventors: Jeffrey R. Brender, James B. Mitchell, Kazutoshi Yamamoto, Shun Kishimoto, Jeeva P. Munasinghe, Hellmut Merkle, Murali K. Cherukuri
-
Publication number: 20190083647Abstract: The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.Type: ApplicationFiled: September 26, 2018Publication date: March 21, 2019Applicants: Aura Biosciences, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Ser.Inventors: Elisabet de los Pinos, John Todd Schiller, Rhonda C. Kines, John MacDougall
-
Publication number: 20180133253Abstract: Methods of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of peripheral blood mononuclear cells (PBMCs) from a sample of peripheral blood; (b) specifically selecting CD8+ T cells that also express PD-1 and/or TIM-3 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells are disclosed. Related methods of administering a cell population enriched for tumor-reactive T cells to a mammal, methods of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, and isolated or purified cell populations are also disclosed.Type: ApplicationFiled: November 15, 2017Publication date: May 17, 2018Applicant: The United States of America,as represented by the the Secretary, Department of Health and Human SerInventors: Alena Gros, Steven A. Rosenberg
-
Publication number: 20170290904Abstract: The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.Type: ApplicationFiled: September 3, 2015Publication date: October 12, 2017Applicants: Bavarian Nordic A/S, Janssen Vaccines & Prevention B.V., The United States of America, as represented by the Secretary Department of Health and Human Ser..Inventors: Ariane VOLKMANN, Robin STEIGERWALD, Ulrike DIRMEIER, Maria Grazia PAU, Benoit Christophe CALLENDRET, Lucy A. WARD
-
Publication number: 20170191119Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.Type: ApplicationFiled: November 2, 2016Publication date: July 6, 2017Applicants: Children's Medical Center Corporation, The United States of America, As Represented by the Secretary, Department of Health & Human Ser.Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
-
Publication number: 20170143851Abstract: Disclosed are imaging agents having the following Formula I: wherein F is a near infrared fluorophore, S is an enzymatically cleavable oligopeptide, Q is a fluorescence quencher molecule, and M is a moiety selected from the group consisting of PEG or derivative thereof and a targeting ligand, and wherein F, Q and M are linked to separate amino acids of the enzymatically cleavable oligopeptide. Compositions comprising such compounds, as well as methods of use, methods of identifying a cell or a population of cells in vivo expressing a protease of interest, and methods of treating a disease through imaging are also disclosed.Type: ApplicationFiled: October 28, 2016Publication date: May 25, 2017Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Ser.Inventors: Xiaoyuan Chen, Seulki Lee, Lei Zhu
-
Publication number: 20160333060Abstract: An isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 1, 2, or 3, wherein the at least eight contiguous amino acids have anti-viral activity, as well as an isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 1, 2, or 3, wherein the at least eight contiguous amino acids have anti-viral activity, a vector comprising such an isolated and purified nucleic acid molecule, a host cell comprising the nucleic acid molecule, optionally in the form of a vector, a method of producing an antiviral polypeptide or conjugate thereof, the anti-viral polypeptide itself, a conjugate or fusion protein comprising the anti-viral polypeptide, and compositions comprising an effective amount of the anti-viral polypeptide or conjugate or fusion protein thereof. Further provided are methods of inhibiting prophylactically or therapeutically a viral infection of a host.Type: ApplicationFiled: January 9, 2015Publication date: November 17, 2016Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SER . . .Inventors: Barry R. O'Keefe, James B. McMahon, Koreen Ramessar, Chang-yun Xiong
-
Publication number: 20140242666Abstract: Disclosed are immunogenic conjugates and therapeutic compositions that include such immunogenic conjugates. Also disclosed are methods of treating and/or inhibiting an Shigella sonnei infection. The disclosed immunogenic conjugates have the general structure: Pr-Sr-O—N?C-Kdo-OS wherein Pr is a carrier protein, Sr is an optional spacer moiety, Kdo is an 3-deoxy-D-manno-octulosonic acid or a derivative thereof, and OS is an oligosaccharide or polysaccharide obtained from S. sonnei. In specific examples, the immunogenic conjugates include the core oligosaccharide obtained from S. sonnei having the structure: wherein R is between 1 and 10 disaccharide repeat units. In specific examples, the disaccharide repeat unit included in the immunogenic conjugate has the structure: ?-L-AltNAcA-3-?-FucNAc4N-4-.Type: ApplicationFiled: May 5, 2014Publication date: August 28, 2014Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Ser, National Research Council of CanadaInventors: John B. Robbins, Rachel Schneerson, Joanna Kubler-Kielb, Christopher P. Mocca, Evguenii Vinogradov
-
Publication number: 20130251704Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: January 16, 2013Publication date: September 26, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Ser.Inventor: The United States of America, as represented by the Secretary, Department of Health and Human Service
-
Publication number: 20130012497Abstract: The invention provides methods of determining an altered susceptibility to develop ADHD, methods of predicting or determining the severity of symptoms of ADHD and associated disorders, and methods of treatment based on the presence or absence of one or more alleles of single nucleotide polymorphism (SNP) markers.Type: ApplicationFiled: May 18, 2012Publication date: January 10, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Ser.Inventors: Maximilian Muenke, Mauricio Arcos-Burgos, Maria Teresa Acosta
-
Publication number: 20110171260Abstract: The present invention relates to an influenza immunogen that includes one or more DNA constructs encoding at least two divergent influenza HAs, wherein each of such one or more DNA constructs encodes one or more of the at least two divergent influenza HAs. Such an immunogen, when administered to a subject, induces an immune response to a plurality of strains of influenza virus, wherein at least one strain of the plurality of strains does not encode any of the divergent influenza HAs encoded by the immunogen. The divergent influenza HAs can be swine influenza HAs or equine influenza HAs, such as influenza H1 HAs or influenza H3 HAs. The invention also relates to a method to use such an immunogen to induce such an immune response as well as to DNA constructs comprising such divergent influenza HAs. Such an immunogen can provide a heterologous as well as a homologous immune response. Such an immunogen can be used to induce an immune response against evolving influenza virus.Type: ApplicationFiled: July 16, 2010Publication date: July 14, 2011Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SER.Inventors: SRINIVAS RAO, GARY J. NABEL, ZHI-YONG YANG, CHIH-JEN WEI, WING-PUI KONG